---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-280149"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:21:16.995034+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi Q3 net loss $11.8M; cash $194.9M funds operations into 2028

## Summary
- Net loss of $11.8M for Q3 2025 vs. $13.2M in Q3 2024; R&D spend down to $10.1M.
- Cash and marketable securities $194.9M at Sept 30, 2025; expected runway into 2028.
- Preparing End-of-Phase 2 meeting request to FDA for IPF chronic cough in Q4 2025.
- Phase 3 program for IPF chronic cough planned to start in H1 2026.
- Phase 2b study for refractory chronic cough (RCC) also targeted for H1 2026.

## SEC filing metadata
- accession: 0001193125-25-280149
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312525280149/0001193125-25-280149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312525280149/trvi-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-280149
- JSON: https://secwatch.observer/filing/0001193125-25-280149.json
- Plain text: https://secwatch.observer/filing/0001193125-25-280149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.